Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients

Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer

(2013) Melissa M. Hudson et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database

(2012) Dana M. Walker et al.   PEDIATRIC BLOOD & CANCER

Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology Group

(2012) Cameron K. Tebbi et al.   PEDIATRIC BLOOD & CANCER

Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database

(2012) Marko Kavcic et al.   PEDIATRIC BLOOD & CANCER

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

(2011) Lynda M. Vrooman et al.   EUROPEAN JOURNAL OF CANCER

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group

(2009) W L Salzer et al.   LEUKEMIA

Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane

(2008) Elly V. Barry et al.   JOURNAL OF CLINICAL ONCOLOGY